CBD strains for medicinal use
Two successful CBD strains have already been successfully developed for medical production
The production and application of cannabinoids in medicine are currently undergoing rapid change. Targeted hemp varieties for medical production are being developed by means of crossing and breeding.
Anyone wishing to successfully develop this process must meet the requirements of patients, doctors and pharmaceutical companies. What is called for is an optimal generation of active ingredients and maximum yield for medical production. However, the specifically developed hemp varieties must also be able to withstand external influences and parasites, ensuring that the cannabidiol (CBD) extracted from the flowers can be further processed as a raw material in medical production.
With CBD 1 (1 % THC, 10 % CBD) and CBD 2 (0.1 % THC, 20 % CBD), Medical Cannabinoids Research & Analysis already has two successful CBD strains that have been specially developed for medical production. Through many years of basic research it has been possible to select CBD strains and propagate cannabis plants in vitro. The complex process guarantees that sterile and virus-free hemp plants can be produced without pesticides – an essential factor in medical production.
Varieties and modes of action
Why is it necessary to have specific cannabis varieties, and what experience is there in relation to this? Every cannabis variety has a specific composition of cannabinoids and terpenes. Essentially, there are three varieties that are used for crossing: Cannabis indica, a small, bushy plant with a relaxing and sedative effect, used, for example, for insomnia, muscle spasm and pain. Cannabis sativa is a large plant with a long flowering period, which has an anti-depressive and stimulating effect, among other things, and is used for ADHS, depression and fatigue for instance. The third variety is formed by hybrids, crossings between Cannabis sativa und indica. Attempts are currently being made to combine the benefits of Cannabis sativa and indica in the hybrids. Knowledge about the varieties and their modes of action plays a decisive role here.
CBD overshadowed by THC
While the active ingredient Tetrahydrocannabinol (THC) has long been at the focus of countless studies, the non-psychoactive and non-euphorigenic Cannabidiol (CBD) has long been underestimated. It was only with in vitro studies that the highly complex pharmacology and the underrated therapeutic potential of CBD came to light. According to the data currently available, antioxidant, anti-inflammatory, anticonvulsive, antiemetic, anxiolytic, hypnotic and antipsychotic effects are being considered as therapeutic effects. In clinical studies with children, GW Pharmaceuticals has just shown positive results of medicines based upon CBD extracts. CBD has a positive effect on certain types of epilepsy such as those of Dravet syndrome and Lennox-Gastaut syndrome. The results are so promising that an accelerated approval procedure – a case of “compassionate use” – can also be expected outside the USA.